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RESEARCH ARTICLE
Pulmonary function decline in amyotrophic lateral sclerosis
TERRY D. HEIMAN-PATTERSON1, OSSAMA KHAZAAL2, DAOHAI YU3,
MICHAEL E. SHERMAN4, EDWARD J. KASARSKIS5, CARLAYNE E. JACKSON6 &
THE PEG NIV STUDY GROUP
1Department of Neurology, Temple University Lewis Katz School of Medicine, Philadelphia, PA USA,
2Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA, 3Department of Clinical Sciences,
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA, 4Department of Medicine, MCG-
Hearst Health, Drexel University College of Medicine, Philadelphia, PA, USA, 5Department of Neurology,
University of Kentucky, Lexington, KY, USA, and 6Department of Neurology, University of Texas Health Science
Center at San Antonio, San Antonio, TX, USA
Abstract
Background: There has been no comprehensive longitudinal study of pulmonary functions (PFTS) in ALS determining
which measure is most sensitive to declines in respiratory muscle strength. Objective: To determine the longitudinal
decline of PFTS in ALS and which measure supports Medicare criteria for NIV initiation first. Methods: Serial PFTs
(maximum voluntary ventilation (MVV), maximum inspiratory pressure measured by mouth (MIP) or nasal sniff pres-
sure (SNIP), maximum expiratory pressure (MEP), and Forced Vital Capacity (FVC)) were performed over 12 months
on 73 ALS subjects to determine which measure showed the sentinel decline in pulmonary function. The rate of decline
for each measure was determined as the median slope of the decrease over time. Medicare-based NIV initiation criteria
were met if %FVC was  50% predicted or MIP was  60 cMH2O. Results: 65 subjects with at least 3 visits were
included for analyses. All median slopes were significantly different than zero. MEP and sitting FVC demonstrated the
largest rate of decline. Seventy subjects were analyzed for NIV initiation criteria, 69 met MIP criteria first; 11 FVC and
MIP criteria simultaneously and none FVC criteria first. Conclusions: MEP demonstrated a steeper decline compared to
other measures suggesting expiratory muscle strength declines earliest and faster and the use of airway clearance inter-
ventions should be initiated early. When Medicare criteria for NIV initiation are considered, MIP criteria are met ear-
liest. These results suggest that pressure-based measurements are important in assessing the timing of NIV and the use
of pulmonary clearance interventions.
Keywords: Pulmonary function, noninvasive ventilation, amyotrophic lateral sclerosis
Introduction
The use of noninvasive ventilation (NIV) has
become a cornerstone treatment for ALS (1). NIV
has been shown to prolong survival and improve
cognition, sleep, and quality of life in patients liv-
ing with ALS (2–7). Current guidelines of the
American Academy of Neurology (AAN) recom-
mend the use of NIV when respiratory symptoms
start or when forced vital capacity (FVC) drops to
<50% of predicted value (1). Clinical practitioners
initiate NIV based on the AAN and Medicare
guidelines. Medicare guidelines for noninvasive
respiratory assistance devices in patients are based
on restrictive lung disease and require that the
patient does not achieve a MIP of at least 60
cmH2O or has a FVC  50% predicted (1,8). In
contrast, the European Federation of Neurological
Societies (EFNS) recommend initiating NIV when
a patient is symptomatic or has a FVC < 80%,
SNIP<40cmH2O, significant nocturnal deatura-
tion, or a morning pCO2> 45 (9). A large survey
of 186 ALS clinicians across US and European
centers underscored the differences in prescribing
behaviors with US specialists influenced by
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Medicare guidelines and insurance reimbursement
while European specialists relied most heavily on
symptoms (10). This underscores the need for
understanding the changes in respiratory function
and what changes should be adopted to provide
optimal utilization of NIV in ALS. In fact, a recent
placebo-controlled study of 54 ALS subjects dem-
onstrated a slower decline in FVC when NIV was
implemented at FVC > 80% (11). Furthermore,
retrospective studies have demonstrated early NIV
initiation can improve survival (12).
While FVC is currently regarded as the stand-
ard indicator of disease progression, previous stud-
ies have suggested that other pulmonary function
measures may be more sensitive indicators of
respiratory dysfunction and could lead to earlier
initiation of NIV (13). Given the impact of NIV
on both quality of life and survival, it is critical
that the implementation of this modality is opti-
mized to maximize its benefits. There has not been
a systematic study of the full spectrum of pulmon-
ary function tests to determine which measure pre-
sages the decline of respiratory muscle strength
and which could provide the optimal criterion for
NIV implementation.
We performed serial pulmonary function tests
over 12 months as a component of a multicenter
pilot study to examine nutrition and NIV in ALS
patients in order to determine the most sensitive
indicator of early decline in respiratory muscle
function. In this way, the decline in the different
measures can be compared to the “standard of
care”. As part of the examination of pulmonary
function decline, we also sought to determine if
Medicare criteria for initiation of NIV were met
first by FVC or if others measures were more sen-
sitive in the ALS population, characterized by pro-
gressive loss of muscle power. Our findings should
inform how NIV is implemented in clinical prac-
tice. Furthermore, by optimizing the start of NIV
to coincide with the earliest signs of respiratory
muscle weakness, the long-term efficacy of this
modality may be enhanced.
Materials and methods
This work was part of a multicenter pilot study of
Nutrition and NIV previously described (14). This
pilot included 5 nutrition-emphasis sites and 7
NIV-emphasis sites. The NIV emphasis sites
employed a stratified design and entered patients
into two groups based on the best sitting forced
vital capacity (FVC): Group 1, 80–95% of pre-
dicted in the NIV Arm and Group 2, 50–79% of
predicted. The overall goal of the NIV arm in this
pilot study was to determine the rate of NIV
acceptance and tolerance with early intervention
(FVC at 80%) vs. standard of care (50%) and to
identify factors that influence acceptance and
tolerance of NIV at each level. In this regard,
Group 1 was started on NIV when the FVC fell to
80% and Group 2 was initiated on NIV when the
FVC fell to 50%.
An additional goal of this study, reported in
this manuscript, was to determine the earliest and
most rapid changes of respiratory dysfunction. To
this end, subjects in the NIV arm were evaluated
at baseline, 8,16,24,32,40 and 48 weeks with pul-
monary functions measured with patients in an
upright sitting position including: Forced sitting
vital capacity (SFVC), sniff nasal pressure
(SSNIP), maximal inspiratory pressure (MIP),
maximal expiratory pressure (MEP), and maximal
voluntary ventilation (MVV). Additionally, because
of known effects of position on diaphragm func-
tion, SNIP and FVC were also measured in the
supine (lying) position (LSNIP and LFVC). FVC
and MVV were measured by spirometry
(Respironics Renaissance). Pressure measurements
were measured using a portable electronic pressure
meter (MicroMedical). All measures except for
MVV were performed in triplicate and the highest
value for each measure was used for analysis. Vital
capacities are reported as percent predicted nor-
mal; respiratory pressures were measured as cm
H2O, and MVV measured in liters/minute. The
best value of 3 efforts was used for analysis. For
patients with bulbar dysfunction who were unable
to keep a mouth seal, face masks with a soft seal
to prevent air leaks were used to perform the pul-
monary function measures. In examining the
slopes of declines we utilized only participants who
completed at least three visits so that we had at
least three data sets to create the slope.
Additionally, we examined for any differences
between Group 1 subjects and Group 2 subjects in
order to see if there were changes in the rate of
progression as pulmonary function deteriorated.
We also collected the ALSFRS-R functional rating
score in order to determine whether the rate of
pulmonary decline was correlated with the rate of
functional decline. Finally, we also examined
whether MIP or FVC met Medicare criteria earlier
(defined as FVC of  50% of predicted or MIP
was  60 cMH2O).
Statistical methods
Data were expressed as counts and percentages for
categorical variables and median (range or inter-
quartile range) for continuous variables overall as
well as by disease group. For each measure, we
obtained the subject-specific slope by using the
best-fitted line of all the longitudinal values for
that subject. The rate of decline of each pulmon-
ary function parameter was then estimated using
the median of subject-specific slopes for the abso-
lute drops over time. In this way, we could deter-
mine if any of the pulmonary functions might
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serve as an earlier index of respiratory insufficiency
when compared to the FVC. Given that most of
the pulmonary function measures were not nor-
mally distributed, we used non-parametric tests
such as the Wilcoxon rank-sum test to compare
the respiratory decline measures between groups as
well as to test whether each slope was significantly
different from 0 with each group or overall.
Spearman correlation coefficient was employed for
correlation analyses between variables of interest
(e.g. among slopes of decline or between slopes of
decline and baseline PFTs). A mixed-effects model
was also used to determine if the slopes in time were
significantly different than zero within each group or
from each other between two groups via an inter-
action term between time and group, after having
adjusted for possible confounders or effect modifiers
(i.e. age, gender, and household income) while at
the same time to account for the correlation among
the observations from the same patients over time.
Multiple testing adjustments were not made due to
the exploratory nature of this study. p-values less
than 0.05 were considered statistically significant.
SAS version 9.4 (SAS Institute Inc., Cary, NC) was
used for all the data analyses.
Results
73 subjects (63%, male (n¼46), 37% female
(n¼27)) enrolled with a median age (range) of
58(36,82) years. Sixty-five subjects (42 in Group 1
and 23 in Group 2) had at least 3 visits and were
used for the analysis of pulmonary function decline
(median follow-up (range) 336 (73–371) days).
The demographic characteristics of this group are
presented in Table 1. Over the interval measured,
all of the longitudinal rates of decline for the 9
PFTs and ALSFRS scores were statistically signifi-
cantly different than 0 (Table 2, p-value not
shown). MEP showed the greatest decline among
all measures (2.60%/month) compared to MIP
(1.59%/month), sFVC (2.01%/month), LFVC
(2.02%/month), MVV (1.62%/month), SNIP
(1.25%/month) and LSNIP (1.42%/month)
(Table 2, Figure 1). When comparing the rate of
decline between Group 1 and Group 2, there were
no statistically significant differences irrespective of
NIV use.
Correlations between the baseline values of the
pulmonary functions were calculated using
Spearman correlation coefficients. We found that
all of the baseline values were significantly posi-
tively correlated with each other except for MEP
and the LFVC, although the strength of associ-
ation varied from poor to fair (e.g. between
LSNIP and SSNIP or LFVC and SVC). (Table
3). We also examined the association between the
baseline value of each pulmonary function and the
rate of decline for all of the variables (Table 4).
We found that the baseline MIP was significantly
negatively associated with the rate of decline in
both MIP and MEP. Similarly, the baseline MEP
was correlated with the slope of change in MEP
and MIP. There was also a significant (mostly fair)
negative association between the baseline SNIP
and the rate of decline in MIP, MEP and LSNIP
Table 1. Baseline demographics and disease characteristics for patients with 3 visits.
Variable
Overall Group 1 Group 2
(n565) (n5 42) (n5 23)
Age (years) 58.19 (35.83, 82.03) 55.69 (35.83, 82.03) 63.71 (40.58, 77.58)
Gender, N (%)
F 23 (35.38%) 14 (33.33%) 9 (39.13%)
M 42 (64.62%) 28 (66.67%) 14 (60.87%)
BMI 26.07 (18.83, 40.26) 26.75 (18.83, 38.77) 25.94 (20.66, 40.26)
Site of Onset, N (%)
Bulbar 12 (18.5%) 6 (14.3%) 6 (26.1%)
Extremity 53 (81.5%) 36 (85.7%) 17 (73.9%)
Sitting FVC % Predicted 82.0 (47.00, 96.0) 89.0 (74.0, 96.0) 61.0 (47.0, 76.0)
Laying FVC % Predicted 69.5 (28.0, 102.0; n¼56) 80.0 (33.0, 102.0; n¼37) 48.0 (28.0, 69.0; n¼19)
MIP cm H2O 39.0 (4.0, 86.0, n¼59) 43.0 (17.0, 86.0; n¼39) 22.0 (4.0, 86.0; n¼20)
Sitting SNIP cm H2O 46.0 (10.0, 102.0; n¼59) 55.5 (10.0, 100.0; n¼38) 30.0 (19.0, 102.0, n¼21)
Laying SNIP cm H2O 46.0 (3.0, 114.0; n¼55) 56.0 (15.0, 102.0; n¼36) 34.0 (3.0, 114.0; n¼19)
MEP cm H2O 53.0 (9.0, 141.0; n¼59) 60.0 (9.0, 141.0; n¼39) 33.5 (16.0, 98.0; n¼20)
SMVV L/min 53.3 (4.8, 172.9; n¼55) 63.2 (29.9, 172.9; n¼36) 36.6 (4.8, 95.0; n¼19)
ALS FRS 35.5 (15.0, 45.0; n¼64) 36.0 (22.0, 45.0; N¼41) 35.0 (15.0, 43.0; n¼23)
Follow up (days) 336 (73, 371) 336 (120, 371) 284 (73, 347)
Number of Study Visits,( N) 65 42 23
Mean (SD) 6.51 (1.56) 6.81 (1.44) 5.96 (1.66)
Median (IQR) 7.00 (5.00, 7.00) 7.00 (6.00, 8.00) 6.00 (5.00, 7.00)
Median (Range) 7 (3, 10) 7 (4, 9) 6 (3, 10)
Table entries are median (range) or count (%); data was obtained on all subjects except where n is indicated.Group 1 subjects were
>80-95% FVC on study entry and Group 2 were those subjects with FVCs 50-79%. Abbrev SSNIP refers to SNIP in the sitting
position and LSNIP in the labing position.
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as well as between the baseline LSNP and the rate
of decline of MIP, MEP, or LSNIP. The baseline
ALSFRS-R score was weakly but significantly posi-
tively associated with the rate of decline in SFVC
and SSNIP. The rate of decline in each of the
measured pulmonary functions significantly and
positively associated with the rate of decline of all
the other parameters except for the rate of decline
between MEP and LFVC where p¼ 0.065
(Table 5).
All seventy-three subjects were analyzed for cur-
rent NIV initiation criteria (defined by %FVC and
MIP only). Overall, 69 met IP criteria first, 11 met
FVC and IP criteria simultaneously, and none met
FVC criteria first. Fifty-five subjects met NIV
initiation criteria based on IP alone at baseline visit,
whereas only 3 met criteria at baseline based on FVC.
Thirty-two of the subjects that met NIV criteria by IP
never dropped their FVCs low enough to qualify.
Discussion
This pilot study demonstrates that MEP changes fast-
est from the baseline in patients with ALS compared
to the other pulmonary function measures, suggesting
a more rapid deterioration of expiratory muscle
strength. In fact, MEP changes more rapidly than
MIP and FVC which are used to determine eligibility
for NIV initiation. Given that the present criteria do
not consider MEP and that the criteria to initiate
Table 2. Rate of decline per month in PFTs and ALS FRS scores overall and by groupa.
Variable
Overall Group 1 Group 2 p-Value
(n565) (n542) (n523) Group 1 vs. 2
SFVC Max 2.01 (10.85, 2.28) 1.97 (8.91, 2.28) 2.32 (10.85, 0.34) 0.84
LVFVC Max 2.02 (11.27, 2.15) n¼55 2.03 (7.26, 1.96) n¼38 1.83 (11.27, 2.15) 0.67
MEP Max 2.60 (9.89, 3.81) n¼64 2.70 (9.89, 3.81) 2.44 (7.64, 1.52) n¼22 0.23
MIP Max 1.59 (8.36, 2.25) n¼64 2.27 (8.36, 2.25) 0.88 (6.07, 0.92) n¼22 0.21
SSNIP Max 1.25 (7.23, 5.49) n¼64 1.09 (7.23, 5.49) 1.39 (4.13, 0.98) n¼22 0.99
LSNIP Max 1.42 (6.77, 1.56) n¼54 1.36 (6.67, 1.56) n¼38 1.56 (6.77, 0.40) n¼16 0.63
SMVV 1.62 (10.92, 5.32) n¼58 2.48 (10.92, 5.32) n¼40 0.47 (6.98, 0.62) n¼18 0.06
ALS FRS 1.13 (2.54, 0.20) n¼51 1.13 (2.35, 0.20) n¼36 1.13 (2.54, 0.30) n¼15 0.47
ALS FRS
Respiratory Domains
0.27 (0.89, 0.12), n¼51 0.21 (0.89, 0.12) n¼36 0.50 (0.74, 0.02) n¼15 0.09
aTable entry¼median slope (range) of decline on a monthly basis (range), where 3 values for a measure were not available on all
subjects within a category, the number of subjects (n) with available measures is indicated. These declines are based on %drop from
baseline. For the Overall Group all the values were significantly different from 0 (p<0.01). Declines were not significantly different
between Groups 1 and 2 (p-value Group 1 vs. 2 column).
Figure 1. Median overall decline in pulmonary functions over time. This figure demonstrates the decline from origin at time 0 and
measured in absolute change in % over time. Note the most rapid decline occurs in the MEP followed by the laying FVC and
inspiratory pressures (supine SNIP and MIP). This suggests that pressure measurements should be part of clinical assessments of
respiratory function and both be used for determining initiation of NIV.
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NIV were met earlier using MIP, there is clearly a
need to consider MEP in determining both respira-
tory muscle function and timing of NIV in the clinical
setting. Furthermore, it may be useful to integrate
MEP and MIP into clinical trials both as part of entry
criteria and pulmonary endpoints. Since MEP
declines fastest it may be a more sensitive respiratory
measure to detect a clinical effect.
Table 3. Overall correlations among baseline values of pulmonary functions.
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
SFVC LFVC MIP SSNIP LSNIP MEP SMVV
SFVC 1.00000 0.83 0.45 0.34 0.41 0.32 0.401
– <.0001 0.0003 0.009 0.002 0.01 0.002
65 56 59 59 55 59 55
LFVC 0.83 1.00 0.43 0.41 0.47 0.23005 0.278
<0.0001 – 0.001 0.002 0.0003 0.088 0.047
56 56 56 55 55 56 55
MIP 0.45 0.43 1.00 0.76 0.74 0.59 0.56
0.0003 0.0009 – <0.0001 <0.0001 <0.0001 <0.0001
59 56 59 58 55 59 55
SSNIP 0.34 0.41 0.76 1.00 0.89 0.52 0.46
0.009 0.002 <.0001 – <.0001 <.0001 0.0004
59 55 58 59 55 58 55
LSNIP 0.41 0.47 0.74 0.89 1.00 0.48 0.440
0.002 0.0003 <.0001 <.0001 – 0.0002 0.0008
55 55 55 55 55 55 55
MEP 0.32 0.23 0.59 0.52 0.48 1.00 0.53
0.01 0.09 <.0001 <.0001 0.0002 – <.0001
59 56 59 58 55 59 55
SMVV 0.40 0.27 0.56 0.46 0.44 0.53 1.00
0.002 0.047 <.0001 0.0004 0.0008 <.0001 –
55 55 55 55 55 55 55
Table 4. Overall correlations between baseline values of pulmonary functions and ALS FRS score with rates of their decline over
time.
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
SFVC LFVC MIP_ SSNIP LSNIP MEP SMVV FRS_Total
Slope_SFVC 0.01 0.06 0.03 0.02 0.04 0.04 0.04 0.29
0.946 0.635 0.820 0.878 0.792 0.763 0.749 0.018
65 56 59 59 55 59 55 64
Slope_LFVC 0.05 0.19 0.035 0.03 0.03 0.09 0.07398 0.25
0.704 0.191 0.810 0.827 0.864 0.547 0.613 0.072
55 50 50 50 49 50 49 54
Slope_MIP 0.11 0.10 0.57 0.42 0.39 0.41 0.20 0.08
0.371 0.463 <.0001 0.0008 0.004 0.001 0.13555 0.558
64 56 59 59 55 59 – 63
Slope_SSNIP 0.17 0.11 0.12 0.28 0.13 0.20 0.06 0.32
0.18 0.414 0.351 0.030 0.336 0.129 0.669 0.012
64 56 59 59 55 59 55 63
Slope_LSNIP 0.01 0.03 0.25 0.24 0.46 0.19 0.16 0.02
0.925 0.841 0.077 0.092 0.001 0.192 0.274 0.864
54 50 50 50 49 50 49 53
Slope_MEP 0.10 0.034 0.46 0.34 0.31 0.61 0.31 0.11
0.419 0.787 0.0002 0.009 0.02 <.0001 0.021 0.413
64 56 59 59 55 59 55 63
Slope_SMVV 0.13 0.12 0.20 0.17 0.24 0.23 0.51 0.17
0.333 0.383 0.140 0.213 0.084 0.086 <0.0001 0.193
58 54 55 54 53 55 53 57
Slope_ALSFRS_ 0.12 0.07 0.08 0.002 0.03 0.07 0.01 0.02
0.402 0.660 0.572 0.990 0.824 0.659 0.923 0.872
51 47 48 47 46 48 46 50
Values are bolded because they reached statistical significance of p < 0.05.
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Additionally, we have demonstrated that there
is a correlation between all the baseline measures
of respiratory function and their changes over time
as well as with functional changes as measured by
the ALSFRS-R score. This supports the similar
findings of correlation between ALSFRS-R and
FVC that have previously been published (15).
However, our study includes longitudinal follow
up of not only FVC but measures of muscle
strength (MEP and MIP), measures of fatigue,
and positional effects on FVC and SNIP.
Furthermore, given that expiratory muscle strength
declines fastest, attention needs to be given to the
implementation of mechanical insufflation/exsuffla-
tion (MI-E) devices. Generally, MI-E devices are
prescribed based on peak cough flow and while we
did not measure peak cough flow, it is likely that
reduced expiratory pressures would lead to a
decrease in the peak cough flow. This suggests
that closer attention should be given to this meas-
ure as well.
We also noted no differences in the rates of
decline between Group 1 (earlier in disease) and
Group 2 irrespective of whether they were on or
off NIV. However, this study was not powered to
examine the actual effects of NIV on PFT decline.
Beyond using pressure as a criterion to initiate
NIV in ALS in addition to lung volumes, the
results of this study have pathophysiological
importance. As an ALS patient develops weakness
of the diaphragm and accessory muscles of inspir-
ation, clearly tidal volume can decrease without
the patient experiencing dyspnea. However, it is
common that the ALS patient demonstrates bibasi-
lar atelectasis and experiences difficulty with
coughing and airway clearance, functions that
require expiratory muscle power. The finding that
MEP changes are early and more rapid than other
objective measures or respiratory decline is sup-
portive of these clinical observations regarding
poor pulmonary clearance and suggests that these
clearance issues may precede the need for noninva-
sive ventilation.
The use of measurements of inspiratory respira-
tory muscle strength to determine a need for venti-
lation is commonly used in other settings. For
instance, when following patients with rapidly-
evolving weakness in the ICUs, it is common clin-
ical practice to measure serial MIPs to determine
the timing of intubation. The basis for this deter-
mination rests on the recognition of the impending
critical failure of adequate ventilation, meaning
failure to deliver adequate volumes of ventilation.
The implication is that weakness precedes failure
to deliver tidal volume. This is exactly the same
pathophysiological argument for ALS albeit on a
different time base. It seems reasonable that opti-
mal clinical practice in ALS would favor the insti-
tution of NIV based on serial measurement of
MIP and MEP rather than %FVC. MEP may also
be useful in predicting the need for airway clear-
ance support (such as training in quad-cough or
MIE devices). Similarly, it would follow that serial
Table 5. Correlations among the rates of decline for PFTS and ALS FRS with each other over time.
Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
Slope_SFVC Slope_LFVC Slope_MIP_ Slope_SSNIP Slope_LSNIP Slope_MEP_ Slope_SMVV Slope_ALSFRS
Slope_SFVC 1.00 0.68 0.48 0.65 0.58 0.35 0.59 0.78
– <0.0001 <0.0001 <0.0001 <0.0001 0.0044 <0.0001 <0.0001
65 55 64 64 54 64 58 51
Slope_LFVC 0.68 1.00 0.38 0.58 0.44 0.25 0.42 0.67
<0.0001 – 0.004 <0.0001 0.001 0.065 0.002 <0.0001
55 55 55 55 54 55 53 48
Slope_MIP 0.48 0.38 1.00 0.55 0.47 0.66 0.48 0.57
<0.0001 0.0044 – <0.0001 0.0003 <.0001 0.0001 <0.0001
64 55 64 64 54 64 58 51
Slope_SSNIP 0.65 0.58 0.55 1.00 0.65 0.57 0.44 0.64
<0.0001 <0.0001 <0.0001 – <0.0001 <0.0001 0.001 <0.0001
64 55 64 64 54 64 58 51
Slope_LSNIP 0.58 0.44 0.47 0.65 1.00 0.56 0.42 0.51
<0.0001 0.0009 0.0003 <0.0001 – <0.0001 0.002 0.0002
54 54 54 54 54 54 53 48
Slope_MEP 0.35 0.25 0.66 0.57 0.56 1.00 0.41 0.43
0.004 0.065 <0.0001 <0.0001 <0.0001 – 0.002 0.002
64 55 64 64 54 64 58 51
Slope_SMVV 0.59 0.42 0.48 0.44 0.42 0.41 1.0 0.59
<0.0001 0.002 0.0001 0.001 0.002 0.002 – <.0001
58 53 58 58 53 58 58 50
Slope_ALSFRS 0.78 0.67 0.57 0.64 0.51 0.43 0.59 1.00
<0.0001 <0.0001 <0.0001 <0.0001 0.0002 0.002 <0.0001 –
51 48 51 51 48 51 50 51
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measures of MIP and MEP could also serve as an
informative endpoint in clinical drug trials in ALS.
Importantly, reduction in inspiratory and
expiratory pressures may be a modifiable risk fac-
tor for respiratory failure. It has been shown that
due to small fiber size, abundance of capillaries,
and a high aerobic oxidative enzyme activity, dia-
phragm muscle fibers are resistant to fatigue while
intercostal muscles are less resistant due to their
fiber type composition. However, the structural
and functional characteristics of respiratory muscle
fibers are not fixed and can be modified in
response to training (16). In fact, expiratory
muscle training in ALS subjects demonstrated
improved MEP as well as swallowing function over
8 weeks of in-home training (17).
In summary, we would recommend that muscle
strength as measured by inspiratory and expiratory
pressures should be considered in determining the
institution of NIV in clinical settings. We would
further advocate for additional studies that exam-
ine the impact of muscle training on respiratory
function and survival be undertaken and that these
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